877TO STUDY OF PALLIATIVE THERAPY OF REFRACTORY DYSPNEA WITH SMALL DOSE TRANSDERMAL PUT IN BUPRENORPHINERefractory dyspnea is a major symptom of chronic obstructive pulmonary disease patients It is represent as persisting proceedings of dyspnea despite most reliable trendy therapy inclusive of, however no longer constrained to smoking cessation, training, inhaled bronchodilators and pulmonary physiotherapy. The aim of this study an objective study of palliative therapy of refractory dyspnea with small dose transdermal put in Buprenorphine. Before making use of BUP, dyspnea changed into scored on numerical analog scales and the sufferers were examined by evaluation of essential parameters, questionnaires. Than treatment with TD BUP (2.5 ?g/h or 5 ?g/h changed into commenced. 48 to 72 hours later the sufferers were surveyed once more. We should survey N = 26 patients with refractory breathlessness. All our patients had severest base-line dyspnea (MRC 3: 10.4%, MRC 4: 77.6%) and a high symptom burden. Taken together we treated mainly elderly, terminal ill cancer patients. A high quality effect at the subjective feeling of dyspnea as well as on its path physiology: Dropping the pressure-prompted tachycardia and hyperventilation ends in less oxygen intake. Our document indicates in addition arguments now not to keep away from opioids and helps to lessen reservations. The treatment of dyspnea receives advanced and sufferers will advantage from buprenorphinedrpebyreddy@gmail.comResearch1122020 COPD, buprenorphine, oxygen saturation, breathlessnessKedarasetty Vijaya Kumar1, Srikanth Reddy Dumpa2Associate Professor, Department of Anaesthesiology, Sree Balaji Medical College and Hospital, Chrompet, Chennai (Affiliated to Bharath University, Chennai), India 2* Associate Professor, Department of Orthopaedics, Sri Lakshmi Narayana Institute of Med